American Academy of Neurology 2013
Described by the AAN as â€œthe world's most important annual event for neurologists and neuroscience professionals,â€ the 2013 annual meeting will offer cutting-edge scientific presentations and comprehensive educational programs to more than 10,000 attendees from across the globe.
Novel Cerebrospinal Fluid Biomarkers Can Be Used to Distinguish Underlying Pathology in Patients with Specific Form of Dementia
Droxidopa Shows Promise as a Treatment for Neurogenic Orthostatic Hypotension Symptoms in Patients with Parkinson's Disease
Comparison of Newer and Traditional Antiepileptic Drugs in the Treatment of Epilepsy Induced by MELAS
Teriflunomide Reduces Relapse-Related Sequelae, Hospitalizations and Corticosteroid Use in Multiple Sclerosis Patients
BG-12 Shows Clinical, Neuroradiologic Efficacy in U.S. Patients with Relapsing-Remitting Multiple Sclerosis
The Long-Term Safety of an Oral, Extended-Release Capsule Formulation of Carbidopa-Levodopa (IPX066) in Patients with Early and Advanced Parkinson's Disease
New Sports Concussion Guideline from the AAN Says Athletes with Suspected Concussion Should Be Removed from Play
Results of the MOTION and SETTLE Trials Investigating the Use of Safinamide as Add-On Therapy to Dopamine Agonist and Levodopa
Fernando Figueira, MD, and his associates from the Hospital SÃ£o Francisco, in Rio De Janeiro, Brazil, called for expanded requirements for "disease-free" designation in multiple sclerosis (MS) patients in a Multiple Sclerosis Treatment poster session at the American Academy of Neurology (AAN) 2013 Annual Meeting.
In the Multiple Sclerosis Treatment Safety poster session at the American Academy of Neurology (AAN) 2013 Annual Meeting, Barry Singer, a neurologist at the Missouri Baptist Medical Center, in St. Louis, and founder and director of the MS Center for Innovations in Care, and his co-authors presented an analysis of infection rates in three placebo-controlled teriflunomide studies.
In the Multiple Sclerosis Treatment Safety poster session at the American Academy of Neurology (AAN) 2013 Annual Meeting, Paul O'Connor, of St. Michael's Hospital, in Toronto, and his colleagues presented a study designed to determine whether immune responses to seasonal influenza vaccination are preserved in teriflunomide-treated patients with relapsing forms of multiple sclerosis (RMS).